“`html
Introduction
Table of Contents
Hypertension affects more than 115 million adults in the US and represents the most prevalent and modifiable risk factor for the development of cardiovascular diseases (CVDs).1 The American Heart Association (AHA) and American College of cardiology (ACC) have recently furnished an updated 2025 guideline1 for the prevention, diagnosis, and management of hypertension to replace the 2017 version.2 This update is pertinent given the historic differences in clinical recommendations for hypertension care between US professional societies and their international counterparts. This article summarizes notable updates of the 2025 AHA/ACC guideline for hypertension care.
Blood Pressure Treatment Threshold
in determining blood pressure (BP) treatment threshold and the use of CVD risk estimation to guide drug treatment of hypertension,the use of the PREVENT scale is now recommended. The PREVENT scale was developed in 2023 to assess broad cardiovascular risk, such as the risk of developing atrial
Additionally, one new advice in the context of resistant hypertension entails screening for primary aldosteronism in adults with the condition nonetheless of the presence of hypokalemia. It is indeed also recommended not to discontinue antihypertensive medications, accept for mineralocorticoid receptor antagonists, in the time frame leading up to the initial screening.
Comorbidities
A previous recommendation to treat hypertension with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) in the presence of diabetes and albuminuria has been elaborated on. The new guidelines recommend treatment with an ACEi or ARB specifically in the presence of CKD with an estimated glomerular filtration rate of below 60 mL/min/1.73 m2 or albuminuria greater than 30 mg/g, and to consider treatment in patients with milder albuminuria (<30 mg/g). Additionally, in patients with CKD, treatment with an ACEi or ARB is not only indicated to delay progression to diabetic kidney disease but also to reduce the risk of CVD.
Complications
If an adult patient develops an acute intracerebral hemorrhage (ICH) with an SBP between 150 and 220 mm Hg, it is newly recommended to aim to lower the SBP to 130 to 139 mm Hg and maintain this SBP for at least 7 days. Though, if SBP drops below 130 mm Hg, then antihypertensives should be stopped. Careful titration in lowering the SBP is pertinent to avoid peaks and large variability in SBP with the goal of improving functional outcomes post ICH. Moreover, in patients with acute ischemic stroke who undergo accomplished endovascular treatment for large vessel occlusion, lowering the SBP below 140 mm hg within 24 to 72 hours after reperfusion can worsen long-term functional outcomes.
Furthermore,in nonpregnant and nonstroke adult patients with severe hypertension who are hospitalized for noncardiac conditions,it is not recommended to use intravenous or oral antihypertensives intermittently for the purpose of acute BP reduction. Notably, the term severe hypertension has been introduced in this guideline to replace the term hypertensive urgency, with severe hypertension still defined as a BP of greater than 180/120 mm Hg without evidence of acute target organ damage.
Regarding dementia and hypertension, the guidelines newly specify a treatment goal below 130-mm Hg SBP to prevent mild cognitive impairment and dementia.
Pregnancy
Several recommendations have been updated for pregnant women with hypertension. Firstly, pregnant patients with an SBP of 160 mm Hg or greater or a DBP of 110 mm Hg or greater confirmed on repeat reading within 15 minutes should be treated to lower the BP to less than 160/less than 110 mm Hg within 30 to 60 minutes. Secondly, p
Okay, I will analyze the provided text and follow the three-phase process as instructed.
Provided Text:
<h6>1. World Health Association. <em>Global status report on noncommunicable diseases 2023</em>. Geneva: World Health Organization; 2023. <a href="https://iris.who.int/server/api/core/bitstreams/f062769d-f075-4a00-87af-0a2106e0bd04/content">https://iris.who.int/server/api/core/bitstreams/f062769d-f075-4a00-87af-0a2106e0bd04/content</a></h6><h6 class="pb-4 pt-2 text-sm">2. Tsao CW, aday AW, Cole SK, et al. Temporal trends in cardiovascular disease mortality in the United States, 2000-2019. <em>J am Coll Cardiol.</em> 2021;78(17):1701-1712.doi:10.1016/j.jacc.2021.08.008</h6><h6 class="pb-4 pt-2 text-sm">3.Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. <em>Circulation.</em> 2022;145(8):e154-e616. doi:10.1161/CIRCULATIONAHA.121.055937</h6><h6 class="pb-4 pt-2 text-sm">4. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. <em>N Engl J med. </em>2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939</h6>PHASE 1: ADVERSARIAL RESEARCH, FRESHNESS & BREAKING-NEWS CHECK (as of 2026/01/29 12:06:01)
I will verify each citation independently.
- World health Organization. Global status report on noncommunicable diseases 2023. geneva: World Health organization; 2023.
* Verification: The WHO published the Global status report on noncommunicable diseases 2023 in 2023. the link provided leads directly to the report on the WHO’s Iris platform. WHO Website.
* Breaking news Check: As of January 29,2026,the WHO has released the Global status report on noncommunicable diseases 2024 in December 2024. WHO Website.
- Tsao CW, Aday AW, Cole SK, et al.Temporal trends in cardiovascular disease mortality in the United States, 2000-2019. J Am Coll Cardiol. 2021;78(17):1701-1712. doi:10.1016/j.jacc.2021.08.008
* Verification: This article was published in the Journal of the American College of Cardiology in 2021. The DOI resolves correctly. JACC Website.
* Breaking News Check: As of January 29, 2026, newer data on cardiovascular disease mortality trends are available from the CDC’s National Center for Health Statistics (NCHS). Preliminary data for 2020-2022 show continued trends,with some impact from the COVID-19 pandemic. CDC NCHS FastStats.
- Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association.Circulation.2022;145(8):e154-e616. doi:10.1161/CIRCULATIONAHA.121.055937
* Verification: This report was published in Circulation in 2022. The DOI resolves
